1. Medtech Insight
  2. >>Device Area
  3. >>Cardiology

Market Intel: Ever Decreasing Dimensions, Snakes And Origami: The Next-Gen Surgical Robots

 
• By Marion Webb

From "smart" snake-like catheters to miniscule-sized devices, a new generation of surgical robots, developed at world-renowned research institutions, aims to explore a new frontier by allowing doctors to target inaccessible areas within the body, and treat conditions with greater precision and better patient outcomes. With the surgical robotics market projected to surpass $10bn by 2021, a growing number of companies are hoping to capture their share in this trending space.

Robotic-Surgery_1200x675
Next-generation robotic surgical technologies could change the future of medicine

Researchers and companies worldwide are creating innovative, robotically assisted surgical devices that they hope will allow physicians to operate with greater precision and accuracy in the tiniest spaces within the human body, thus improving patient outcomes. The stakes are high with a growing number of competitors vying for their share of the global market opportunity, which is expected to reach more than $10bn by 2021. In this article, we'll take a closer look at the first ever robotically assisted eye surgeries, as well as two early stage robotic systems, developed at UC San Diego and MIT, that could pave a new era for treating atrial fibrillation and stomach issues.

Surgeons at the University Hospitals Leuven (KU Leuven) in Belgium celebrated in January a medical breakthrough by successfully removing blockage...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiology

Injuries And Deaths Linked To Boston Scientific Cardiac Devices. Company Responds

 
• By Brian Bossetta

The US FDA issued a pair of early alerts on Wednesday warning customers about serious adverse events associated with two Boston Scientific cardiac devices. Both alerts include numerous reports of injuries and deaths and are part of the FDA’s ongoing pilot to enhance its recall process.

Ultromics Wins $55M, The Key To Success: Diagnosing Diseases With Available Treatment

 
• By Natasha Barrow

Ultromics has secured $55m in Series C funding to advance its AI tool, EchoGo, which detects undiagnosed heart failure. The company's focus on diseases with available treatments resonated with investors.

Boston Scientific Raises Outlook … Again: Headwinds Offset By EP And Watchman

 
• By Natasha Barrow

Agent drug coated balloon, Watchman product sales, and electrophysiology (EP) business unit growth offset Acurate discontinuation and tariff headwinds. CEO Michael Mahoney shouted out coronary therapies business and answered questions on CMS proposed Ambulatory Surgical Center codes.

Injuries And Deaths Linked To Baxter Infusion Pump

 
• By Brian Bossetta

The US FDA says Baxter has notified customers about an issue with its Novum IQ Syringe Pump that is linked to two deaths and multiple injuries.

More from Device Area

Daye Breaks Into Hormone Self-Testing, Adds New Data To Extensive Gynecology Database

 
• By Natasha Barrow

Daye is launching an at-home reproductive hormone testing service in the UK, utilizing a painless upper arm blood collection method. The product’s UKAS lab accreditation helps build credibility with healthcare providers.

Zimmer Biomet Targets 2027 Launch For Semi-Autonomous Orthopedic Robot After Monogram Acquisition

 
• By Shubham Singh

Zimmer Biomet expects the Monogram deal to meet its financial and strategic criteria, be neutral to adjusted earnings per share from 2025 through 2027 and become accretive thereafter.

Injuries And Deaths Linked To Boston Scientific Cardiac Devices. Company Responds

 
• By Brian Bossetta

The US FDA issued a pair of early alerts on Wednesday warning customers about serious adverse events associated with two Boston Scientific cardiac devices. Both alerts include numerous reports of injuries and deaths and are part of the FDA’s ongoing pilot to enhance its recall process.